Janux Therapeutics, Inc. (NasdaqGM: JANX)
Health Care · Biotechnology · US
$18.17
-1.20% today · -30.0% 1Y
Janux Therapeutics, Inc. (NasdaqGM: JANX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.12B and employs 113 people.
Over the last twelve months the share price has lost 30.0%, trading between 12.12 and 35.34.
Tweenvest scores Janux Therapeutics, Inc. across four factors: quality 42/100, value 59/100. Its strongest factor is value.
JANX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.12B
- Revenue (TTM)
- $24.00M
- P/E
- —
- EPS
- -1.64
- Dividend yield
- —
- Beta (5Y)
- 2.39
- 52-week high
- $35.34
- 52-week low
- $12.12
- Avg volume (3M)
- —
- Shares outstanding
- 61.14M
- Employees
- 113
- Next earnings
- —
About Janux Therapeutics, Inc.
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
- ISIN
- US47103J1051
- Founded
- 2017
- Listed since
- Jun 11, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Bicara Therapeutics Inc.NasdaqGM: BCAX | $1.16B | $17.25 | -1.43% |
| Amoy Diagnostics Co., Ltd.SZSE: 300685 | $1.16B | CN¥20.30 | -4.87% |
| Nanjing Leads Biolabs Co., Ltd.SEHK: 9887 | $1.13B | HK$45.56 | -9.69% |
| L&C BIO Co.,LTDKOSDAQ: A290650 | $1.13B | ₩56,400.00 | +5.03% |
| HOB Biotech Group Corp.,LtdSHSE: 688656 | $1.12B | CN¥120.00 | -8.90% |
| China Resources Boya Bio-pharmaceutical Group Co.,LtdSZSE: 300294 | $1.12B | CN¥14.88 | -0.40% |
| Oncolys BioPharma Inc.TSE: 4588 | $1.11B | ¥5,970.00 | -0.17% |
| Changchun BCHT Biotechnology Co.SHSE: 688276 | $1.10B | CN¥17.79 | -0.89% |
Figures last refreshed Oct 11, 2026.